To elucidate the impact of type I IFN in AML immunosurveillance, we determined the expression levels of IFNA1, IFNA2 and IFNB1 in peripheral blood mononuclear cells (PBMCs) from 132 AML patients (Study Cohort 1; Table 1) by RT-qPCR. Here, IFNB1 is linked to acute myeloid leukemia.